Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Saved in:
| Title: | Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. |
|---|---|
| Authors: | Melero I; Department of Immunology, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain. Electronic address: imelero@unav.es., Yau T; Department of Medicine, University of Hong Kong, Hong Kong, China., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea., Kim TY; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Santoro A; Humanitas University and IRCCS Humanitas Research Hospital - Humanitas Cancer Center, Rozzano, Italy., Sangro B; Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain., Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan., Hou MM; Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan., Matilla A; Hospital General Universitario Gregorio Marañón CIBEREHD, Madrid, Spain., Tovoli F; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Knox J; Princess Margaret Cancer Centre, Toronto, Canada., He AR; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., El-Rayes B; Department of Hematology and Medical Oncology, University of Alabama at Birmingham, Birmingham, USA., Acosta-Rivera M; Fundacion de Investigacion, San Juan, Puerto Rico., Lim HY; School of Medicine, Sungkyunkwan University, Seoul, Korea., Soleymani S; Bristol Myers Squibb, Princeton, USA., Yao J; Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA., Neely J; Translational Medicine, Bristol Myers Squibb, Princeton, USA., Tschaika M; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA., Hsu C; National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Cancer Center, Taipei, Taiwan., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, USA. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jun; Vol. 35 (6), pp. 537-548. Date of Electronic Publication: 2024 May 22. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38844309 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Melero+I%22">Melero I</searchLink>; Department of Immunology, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain. Electronic address: imelero@unav.es.<br /><searchLink fieldCode="AU" term="%22Yau+T%22">Yau T</searchLink>; Department of Medicine, University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Kang+YK%22">Kang YK</searchLink>; Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+TY%22">Kim TY</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Santoro+A%22">Santoro A</searchLink>; Humanitas University and IRCCS Humanitas Research Hospital - Humanitas Cancer Center, Rozzano, Italy.<br /><searchLink fieldCode="AU" term="%22Sangro+B%22">Sangro B</searchLink>; Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Kudo+M%22">Kudo M</searchLink>; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Hou+MM%22">Hou MM</searchLink>; Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Matilla+A%22">Matilla A</searchLink>; Hospital General Universitario Gregorio Marañón CIBEREHD, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Tovoli+F%22">Tovoli F</searchLink>; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Knox+J%22">Knox J</searchLink>; Princess Margaret Cancer Centre, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22He+AR%22">He AR</searchLink>; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22El-Rayes+B%22">El-Rayes B</searchLink>; Department of Hematology and Medical Oncology, University of Alabama at Birmingham, Birmingham, USA.<br /><searchLink fieldCode="AU" term="%22Acosta-Rivera+M%22">Acosta-Rivera M</searchLink>; Fundacion de Investigacion, San Juan, Puerto Rico.<br /><searchLink fieldCode="AU" term="%22Lim+HY%22">Lim HY</searchLink>; School of Medicine, Sungkyunkwan University, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Soleymani+S%22">Soleymani S</searchLink>; Bristol Myers Squibb, Princeton, USA.<br /><searchLink fieldCode="AU" term="%22Yao+J%22">Yao J</searchLink>; Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA.<br /><searchLink fieldCode="AU" term="%22Neely+J%22">Neely J</searchLink>; Translational Medicine, Bristol Myers Squibb, Princeton, USA.<br /><searchLink fieldCode="AU" term="%22Tschaika+M%22">Tschaika M</searchLink>; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.<br /><searchLink fieldCode="AU" term="%22Hsu+C%22">Hsu C</searchLink>; National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Cancer Center, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22El-Khoueiry+AB%22">El-Khoueiry AB</searchLink>; USC Norris Comprehensive Cancer Center, Los Angeles, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2024 Jun; Vol. 35 (6), pp. 537-548. <i>Date of Electronic Publication: </i>2024 May 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38844309 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2024.03.005 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 537 Titles: – TitleFull: Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Melero I – PersonEntity: Name: NameFull: Yau T – PersonEntity: Name: NameFull: Kang YK – PersonEntity: Name: NameFull: Kim TY – PersonEntity: Name: NameFull: Santoro A – PersonEntity: Name: NameFull: Sangro B – PersonEntity: Name: NameFull: Kudo M – PersonEntity: Name: NameFull: Hou MM – PersonEntity: Name: NameFull: Matilla A – PersonEntity: Name: NameFull: Tovoli F – PersonEntity: Name: NameFull: Knox J – PersonEntity: Name: NameFull: He AR – PersonEntity: Name: NameFull: El-Rayes B – PersonEntity: Name: NameFull: Acosta-Rivera M – PersonEntity: Name: NameFull: Lim HY – PersonEntity: Name: NameFull: Soleymani S – PersonEntity: Name: NameFull: Yao J – PersonEntity: Name: NameFull: Neely J – PersonEntity: Name: NameFull: Tschaika M – PersonEntity: Name: NameFull: Hsu C – PersonEntity: Name: NameFull: El-Khoueiry AB IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2024 Jun Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1569-8041 Numbering: – Type: volume Value: 35 – Type: issue Value: 6 Titles: – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology Type: main |
| ResultId | 1 |
